2-(4-amino-1-isopropyl-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-7-ol

ID: ALA5220973

PubChem CID: 136088611

Max Phase: Preclinical

Molecular Formula: C16H16N6O

Molecular Weight: 308.35

Names and Identifiers

Canonical SMILES:  CC(C)n1nc(-c2cc3cccc(O)c3[nH]2)c2c(N)ncnc21

Standard InChI:  InChI=1S/C16H16N6O/c1-8(2)22-16-12(15(17)18-7-19-16)14(21-22)10-6-9-4-3-5-11(23)13(9)20-10/h3-8,20,23H,1-2H3,(H2,17,18,19)

Standard InChI Key:  DWMSSWRQJCJQFL-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 23 26  0  0  0  0  0  0  0  0999 V2000
   -1.6270   -0.1942    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6126    0.6306    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9199   -0.6191    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1309   -0.3779    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1377    0.4020    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3421   -1.0538    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1543   -1.7127    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0867   -2.5016    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8906   -2.6873    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9344   -1.4440    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6559   -1.8439    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3631   -1.4189    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3487   -0.5941    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4967   -3.0852    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3353    1.0776    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1611    1.7365    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9410    1.4678    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9265    0.6431    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0047    2.5438    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6272    3.0852    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4039    2.8197    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5660    2.0114    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3631    1.7978    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  1  3  1  0
  3  4  1  0
  4  5  1  0
  4  6  2  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
 10  7  1  0
  3 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13  1  2  0
  8 14  1  0
 15  5  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18  5  1  0
 16 19  1  0
 20 19  2  0
 21 20  1  0
 22 21  2  0
 17 22  1  0
 22 23  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA5220973

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 308.35

Molecular Weight (Monoisotopic): 308.1386

AlogP: 2.84

#Rotatable Bonds: 2

Polar Surface Area: 105.64

Molecular Species: NEUTRAL

HBA: 6

HBD: 3

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): 4

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 9.50

CX Basic pKa: 3.69

CX LogP: 2.15

CX LogD: 2.15

Aromatic Rings: 4

Heavy Atoms: 23

QED Weighted: 0.53

Np Likeness Score: -0.53

References

1. Oleksak P, Nepovimova E, Chrienova Z, Musilek K, Patocka J, Kuca K..  (2022)  Contemporary mTOR inhibitor scaffolds to diseases breakdown: A patent review (2015-2021).,  238  [PMID:35688004] [10.1016/j.ejmech.2022.114498]

Source

Source(1):

• Scientific Literature